EFEMP1 and lung carcinoma: In contrast, there were significantly lower serum fibulin-3 levels among patients with lung cancer (3.56 ± 2.18 pg/ml) compared with among patients with benign lung diseases and controls (10.16 ± 7.83 and 8.99 ± 2.2 pg/ml, respectively) (P<0.001), with a non-significant difference in the serum levels of fibulin-3 between patients with benign lung diseases and controls (P=0.364) (Table 1).